Strolll has secured £2.1 million in seed investment to help people living with Parkinson’s disease.

The company, based in the West Midlands, has developed digital therapeutics software for augmented reality glasses which transforms physiotherapy and rehabilitation for people living with neurological disorders. 

The patented Reality DTx software uses proprietary methods to alleviate gait and balance motor symptoms experienced by a large number of people with Parkinson’s, while it has potential applications in rehabilitation of other neurological disorders, such as strokes and multiple sclerosis. 

£750,000 of the funding comes from the Midlands Engine Investment Fund (MEIF) through the MEIF West Midlands Equity Fund. The larger round was led by MEIF fund manager Midven, part of the Future Planet Capital Group, in participation with Martlet Capital, SFC Capital and multiple angel investors.

The funding will allow the company to reach several key milestones, including gathering outcomes data from ongoing studies and NHS pilots, expanding into the US market, and demonstrating the ability to apply the technology beyond Parkinson’s disease to other conditions. 

Birmingham Startups 2.0 – nominate now!

“We are excited to use this funding to expand the capabilities of Strolll and look forward to working with Midven, and our investors and partners to make this a reality,” said Jorgen Ellis, CEO. 

“With this investment, we aim to provide an accessible and effective solution for more patients with neurological disorders, ultimately improving their quality of life.”

Birmingham is the booming tech hub the UK didn’t see coming

The tech-driven solution provides gamified exercise therapy through targeted, clinically-proven augmented reality activities. It allows patients to access rehabilitation exercise at home and maintain their disease at a lower stage for longer. 

This improves mobility, confidence, and independence which could reduce the long-term cost burden on families and healthcare systems – with the added benefit of enhancing the patient experience, convenience, and access to rehabilitation.

Huw Sparkes, junior investment manager at Midven, said: “We are thrilled to support Strolll in its mission to transform the lives of people with Parkinson’s disease and relieve strains on the NHS through innovative technology. 

“Its dedication to improving the quality of life for those affected by this debilitating disease is truly inspiring. We look forward to supporting the business growth and further establishing its presence in the UK and backing its expansion worldwide.”

Why slow and steady wins the race in healthcare